Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036218 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
A Phase 3 study of Parkinson Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00036218 is a Phase 3 study of Parkinson Disease that has completed, run by Pfizer. The registered enrollment target is 600 participants, below the 5,324-participant average among 297 other Parkinson Disease trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00036218, a Phase 3 study of Parkinson Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.
Conditions Studied
Interventions
- DRUG sumanirole
- DRUG ropinirole
Study Locations (20)
California
- Pfizer Investigational Site - Carmichael
- Pfizer Investigational Site - Fresno
- Pfizer Investigational Site - Irvine
- Pfizer Investigational Site - La Jolla
- Pfizer Investigational Site - Loma Linda
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Oceanside
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - San Francisco
- Pfizer Investigational Site - San Luis Obiapo
- Pfizer Investigational Site - Walnut Creek
- Pfizer Investigational Site - Walnut Creek
Arkansas
- Pfizer Investigational Site - Hot Springs
- Pfizer Investigational Site - Little Rock
Connecticut
- Pfizer Investigational Site - Fairfield
- Pfizer Investigational Site - New Haven
Florida
- Pfizer Investigational Site - Boca Raton
- Pfizer Investigational Site - Clearwater
Colorado
- Pfizer Investigational Site - Denver
Delaware
- Pfizer Investigational Site - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2001-12 |
| Est. Completion | 2003-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00036218
The ClinicalTrials.gov registry entry for NCT00036218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,324-participant average among 297 other Parkinson Disease trials with a reported enrollment target (89% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which sumanirole is the first listed.
NCT00036218 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arkansas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00036218 about?
NCT00036218 is a clinical study titled "Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.". The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.
What is the current status of trial NCT00036218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2001-12. Estimated completion is 2003-04.
What conditions does trial NCT00036218 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT00036218?
The interventions under investigation include: sumanirole (DRUG), ropinirole (DRUG).
Who is sponsoring clinical trial NCT00036218?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00036218 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
RECRUITING · Phase 3
-
A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's
RECRUITING · Phase 3
-
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
Embryonic Dopamine Cell Implants for Parkinson's Disease
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.